ArticleHepatology (Baltimore, Md.)2026
Hepatic STEAP4 promotes liver regeneration by regulating lysosomal iron homeostasis and membrane integrity in acetaminophen-induced liver injury.
Article in Hepatology (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis in liver biology and diseases.Hepatology communications · 2026Review
- New insights on iron overload-mediated lysosomal membrane rupture in liver regeneration following acetaminophen-induced liver injury.Exploration of digestive diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsUnderstanding the mechanisms behind liver repair in acetaminophen (APAP)-induced liver injury (AILI) is crucial for developing effective treatments. Six-transmembrane epithelial antigen of the prostate 4 (STEAP4) is a metalloreductase involved in iron regulation. The roles of STEAP4 and endolysosomal iron in liver regeneration in AILI remain unclear. APPROACH AND
resultsAlb-Cre- Steap4flox/flox and liver-specific STEAP4 knockout (Alb-Cre+ Steap4flox/flox , L-STEAP4 KO) mice were given APAP for different periods. Deferiprone (DFP) was administered with or after APAP. Biochemical and histological analyses were performed to examine iron homeostasis and liver injury. STEAP4 expression decreased in human AILI livers. APAP treatment lowered hepatic STEAP4 expression in mice. L-STEAP4 KO mice showed similar hepatocyte death and serum ALT levels between 6 and 24 hours, but experienced delayed liver recovery at 48 hours after APAP compared with wild-type mice. Loss of STEAP4 led to iron buildup in endolysosomes, lysosomal membrane damage, and the release of cathepsin B following APAP treatment, which was correlated with lower hepatic mTOR activity, impaired mitophagy, and reduced hepatocyte proliferation 48 hours after APAP. DFP restored mitochondrial and lysosomal functions, providing protection against AILI. Overexpressing STEAP4 or TFEB (a key regulator of lysosomal biogenesis) or post-treatment with DFP repaired lysosomal membranes and inhibited AILI in both wild-type and L-STEAP4 KO mice.
conclusionsSTEAP4 is not essential during the early injury phase but plays a critical role in liver regeneration by maintaining lysosomal iron homeostasis and function after APAP overdose. Targeting STEAP4-mediated endolysosomal iron overload may open new therapeutic avenues for AILI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.